Download PDF
Thromb Haemost 1991; 66(03): 292-294
DOI: 10.1055/s-0038-1646409
Review Article
Schattauer GmbH Stuttgart

Coagulation and Fibrinolytic Activity in Behçet's Disease

K K Hampton
The Department of Medicine, University of Leeds, UK
,
M A Chamberlain
*   Rheumatology and Rehabilitation Research Unit, University of Leeds, UK
,
D K Menon
The Department of Medicine, University of Leeds, UK
,
J A Davies
The Department of Medicine, University of Leeds, UK
› Author Affiliations
Further Information

Publication History

Received 09 August 1990

Accepted 25 February 1991

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Coagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.

 

  • References

  • 1 Chajek T, Fainaru M. Behçet's disease. Report of 41 cases and a review of the literature. Medicine 1975; 54: 179-96
    CrossrefPubMedGoogle Scholar
  • 2 Misbuma Y, Ishikaura K, Veno A. Arterial involvement in Behçet's disease. Jpn J Surg 1973; 3: 52-60
    CrossrefPubMedGoogle Scholar
  • 3 Aronson DL, Thomas DP. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion. Thromb Haemostas 1985; 54: 866-70
    PubMedGoogle Scholar
  • 4 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndroms. Thromb Haemostas 1987; 57: 247-51
    PubMedGoogle Scholar
  • 5 Kluft C, Michiels JJ, Wijngaards G. Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease. Scand J Haematol 1980; 25: 423-30
    PubMedGoogle Scholar
  • 6 Chajek T, Aronovski E, Izak G. Decreased fibrinolysis in Behçet's disease. Thromb Diathes Haemorrh 1973; 29: 610-8
    PubMedGoogle Scholar
  • 7 Mishima H, Masuda K, Shjimada S. et al. Plasminogen activator activity levels in patients with Behçet's syndrome. Arch Ophthalmol 1985; 103: 935-6
    CrossrefPubMedGoogle Scholar
  • 8 Asbeck F, Meyer-Boerneke D, Van de Loo J. Inhibition of the fibrinolytic system in Behçet's disease?. Haemostasis 1977; 6: 303-9
    PubMedGoogle Scholar
  • 9 Inaba G. (ed) Behçet's Disease. Pathogenic Mechanisms and Clinical Features. Proceedings of an International Conference on Behçet's disease, 1981.. Tokyo University Press, Tokyo: 1982
    Google Scholar
  • 10 Aitchison R, Chu P, Cater DR, Harris RJ, Powell RJ. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis 1989; 48: 590-3
    CrossrefPubMedGoogle Scholar
  • 11 Schmitz-Huebner U, Knop J. Evidence for an endothelial cell dysfunction in association with Behçet's disease. Thromb Res 1984; 34: 277-85
    CrossrefPubMedGoogle Scholar
  • 12 Wilson AP, Efthimiou J, Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest 1988; 18: 410-4
    CrossrefPubMedGoogle Scholar
  • 13 Matsuda T, Kaneko K, Hoshi K, Mizushima Y. Platelet function in Behçet's disease. In: Recent Advances in Behçet's Disease.. Lehner T, Barnes CG. (eds) Royal Society of Medicine Services, London: 1986. p 133
    Google Scholar
  • 14 Ritter JM, Barrow SE, Quigley C. Plasma prostacyclin levels in Behçet's disease. Lancet 1985; 2: 497 (letter)
    PubMedGoogle Scholar
  • 15 O'Duffy JD. Suggested criteria for the diagnosis of Behçet's disease. VI Pan Am Congr Rheum Dis 1974: 18
    PubMedGoogle Scholar
  • 16 Yazici H, Tunzun Y, Pazarli H. et al. Influence of age of onset and patients sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9
    CrossrefPubMedGoogle Scholar
  • 17 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46
    CrossrefPubMedGoogle Scholar
  • 18 Laurell CB. Quantitative estimations of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
    CrossrefPubMedGoogle Scholar
  • 19 Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
    PubMedGoogle Scholar
  • 20 Marsh NA. Measurements of fibrinolytic capacity by the euglobulin lysis time - a problem of units. Thromb Res 1977; 12: 197-200
    PubMedGoogle Scholar
  • 21 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijingaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-9
    PubMedGoogle Scholar
  • 22 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast acting inhibitor for tissue type plasminogen activator in human palsma. Thromb Haemostas 1984; 51: 392-5
    PubMedGoogle Scholar
  • 23 Woodhams BJ, Kernoff PBA. Rapid radioimmunoassay for fibrinopeptide A in human plasma. Thromb Res 1981; 22: 407-16
    CrossrefPubMedGoogle Scholar
  • 24 Kudryk B, Robinson D, Netre C, Hessel B, Blombôck M, Blombôck B. Measurement in human blood of fibrinogen/fibrin fragments containing the Bβ15-42 sequence. Thromb Res 1982; 25: 277-91
    CrossrefPubMedGoogle Scholar
  • 25 Knos M, Friberger P. Methods for plasminogen determination in human plasma and for streptokinase standardisation. Prog Chem Fibr Thromb 1979; 4: 154-8
    PubMedGoogle Scholar
  • 26 Hardisty RM, MacPhearson JC. A one stage FVIII AHG assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962; 7: 215-29
    PubMedGoogle Scholar
  • 27 Conard J, Horellou MH, Wechsler B, Blétry O, Godeau P, Samama M. Coagulation and fibrinolysis in 70 patients with Behçet's disease. In: Recent Advances in Behçet's Disease.. Lehner T, Barnes CG. (eds) Royal Society of Medicine Services, London: 1986. p 161
    Google Scholar
  • 28 Efthimiou J, Cambridge G, Harris EN, Snaith ML, Hughes GVR. Anticardiolipin antibodies and vascular complications in Behçet's syndrome. In: Recent Advances in Beheçet's Disease.. Lehner T, Barnes CG. (eds) Royal Society of Medicine Services, London: 1986. p 151
    Google Scholar